(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)
Louvain-la-Neuve, Belgium, January 12, 2026 06:00 PM
Summary of the notification
IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on December 23, 2025.
In its notification, NS Partners Europe S.A indicated that following an acquisition or disposal of securities or voting rights, the 1% threshold has been crossed downwards by NS Partners Europe S.A on 12-12-2025.
Content of the notification
Reason for the notification: Acquisition or disposal of voting securities or voting rights, and downward crossing of the lowest threshold
Notification by: A parent company or controlling person
Persons subject to the notification requirement:
Date on which the threshold is crossed: 12-12-2025
Threshold crossed (in %) : 1%
Denominator : 40.514.619
Notified details: (extract of the received notification form)
Full chain of controlled undertakings through which the holding is effectively held
1. There is no natural person who directly or indirectly holds a sufficient percentage of the voting rights or a sufficient shareholding in the capital of the company.
2. There is no natural person who controls the company by other means (e.g. right to appoint or revoke main directors, veto rights, etc.). As a result, the ultimate controlling persons are the board members: Mr. Paolo FARAONE, Mr. Christophe LENTSCHAT, and Mr. Grégoire NOTZ.
Additional information
Partners Europe S.A., acting as AIFM of the fund Lux-Investment Professionals SICAV-FIS S.A. NS Partners Europe S.A., in agreement with Lux-Investment Professionals SICAV-FIS S.A. prospectus and the AIFM Voting right policy, may exercise the voting rights on a discretionary basis, without specific instructions from the unit holder of the fund.
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
For further information, please contact:
Elena De Landy
Paralegal: Corporate Affairs and Insurance